TY - JOUR T1 - Expression and clinical significance of S100 calcium binding protein A2 in lung cancer JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2016.PA2868 VL - 48 IS - suppl 60 SP - PA2868 AU - Hui Ren AU - Ting Wang AU - Mingwei Chen Y1 - 2016/09/01 UR - http://erj.ersjournals.com/content/48/suppl_60/PA2868.abstract N2 - S100 family of calcium-binding proteins plays a significant role in the process of many kinds of tumor, including lung cancer, which is the most popular malignancy worldwide. As an important member of this family,S100 calcium binding protein A2 (S100A2) has been confirmed to be associated with many biological processes, and abnormal-expressed S100A2 was observed in NSCLC. However, the S100A2status in lung cancer is still controversial and the expression of S100A2 has not been analyzed in some histological subtypes such as SCLC and Atypical carcinoid. In this study, we evaluated the pattern and distribution of S100A2 in 69 cases of lung cancer including five histological types (27 Adeno carcinma, 26 Squamous cell carcinoma,7 Small cell carcinoma, 3 Large cell carcinoma, 6 Atypical carcinoid) and 20 cases of paired adjacent normal lung tissues by means of immunohistochemistry. Compared with the normal lung tissues (0/20), S100A2 experienced a dramatically upward trend of positive expression, with a positive rate of 38/69(P < 0.001). Specifically, Squamous cell carcinoma, with 19/7, enjoyed the highest expression ratio, followed by Large cell carcinoma (2/1), Adeno carcinoma (16/11), Atypical carcinoid (1/5) respectively, and no S100A2 protein was detected in SCLC. Meanwhile, we firstly demonstrated that the high expression of S100A2 was significantly associated with the incidence of lymph node metastasis in AC (P = 0.018). Our immune-context results demonstrate the association between high S100A2 expression and NSCLC at the tissues level, and S100A2 may serve as an effective biomarker for the diagnosis and prognosis of NSCLC in future. ER -